Search Site
Home >> Research Area >>Neuroscience>>GluR >> (R)-3,4-DCPG
(R)-3,4-DCPG

(R)-3,4-DCPG

Catalog No. BCC7046
Size Price Stock
10mg $215.00 Ship Within 7 Days
50mg $901.00 Ship Within 7 Days
Related Products

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris

Quality Control of (R)-3,4-DCPG

Chemical structure

(R)-3,4-DCPG

Biological Activity of (R)-3,4-DCPG

AMPA receptor antagonist with weak activity at NMDA receptors and little activity at kainate receptors. (RS)-3,4-DCPG and (S)-3,4-DCPG also available.

(R)-3,4-DCPG Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

(R)-3,4-DCPG Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Chemical Properties of (R)-3,4-DCPG

Cas No. 201730-10-1 SDF Download SDF
Chemical Name (R)-3,4-Dicarboxyphenylglycine
SMILES C1=CC(=C(C=C1C(C(=O)O)N)C(=O)O)C(=O)O
Standard InChIKey IJVMOGKBEVRBPP-SSDOTTSWSA-N
Standard InChI InChI=1S/C10H9NO6/c11-7(10(16)17)4-1-2-5(8(12)13)6(3-4)9(14)15/h1-3,7H,11H2,(H,12,13)(H,14,15)(H,16,17)/t7-/m1/s1
Formula C10H9NO6 M.Wt 239.18
Solubility Soluble to 100 mM in water
Storage Desiccate at RT
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other courier with RT , or blue ice upon request.

Preparing Stock Solutions of (R)-3,4-DCPG

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 4.181 mL 20.9048 mL 41.8095 mL 83.619 mL 104.5238 mL
5 mM 0.8362 mL 4.181 mL 8.3619 mL 16.7238 mL 20.9048 mL
10 mM 0.4181 mL 2.0905 mL 4.181 mL 8.3619 mL 10.4524 mL
50 mM 0.0836 mL 0.4181 mL 0.8362 mL 1.6724 mL 2.0905 mL
100 mM 0.0418 mL 0.209 mL 0.4181 mL 0.8362 mL 1.0452 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

References on (R)-3,4-DCPG

Potential antipsychotic and extrapyramidal effects of (R,S)-3,4-dicarboxyphenylglycine [(R,S)-3,4-DCPG], a mixed AMPA antagonist/mGluR8 agonist.[Pubmed: 15215559]


An involvement of glutamatergic transmission in schizophrenia has been postulated for several years. According to that view, hypofunction of NMDA receptors and a compensatory increase in glutamate release which overstimulates non-NMDA receptors contributes to psychotic symptoms. Therefore, potential antipsychotic drugs are searched for among compounds which block AMPA receptors and inhibit glutamate release. (R,S)-3,4-dicarboxyphenylglycine [(R,S)-3,4-DCPG] is a mixed antagonist of AMPA receptors and agonist of an autoreceptor, i.e. metabotropic glutamate receptor 8. The aim of the study was to look for putative antipsychotic properties of (R,S)-3,4-DCPG in the model of locomotor stimulation induced by amphetamine or phencyclidine in mice. Moreover, a risk of extrapyramidal side-effects induced by this compound was examined, as capability to induce catalepsy in the bar test and to increase the proenkephalin mRNA expression, measured autoradiographically in striatal slices by in situ hybridization. (R,S)-3,4-DCPG (80 mg/kg i.p.) decreased the amphetamine (2.5 mg/kg s.c.)-but not phencyclidine (3 mg/kg s.c.)-induced hyperactivity. That dose of (R,S)-3,4-DCPG did not decrease the spontaneous locomotor activity of mice. However, a dose of 100 mg/kg ip of that compound evoked catalepsy and enhanced the catalepsy and striatal proenkephalin mRNA expression induced by haloperidol (1-2 mg/kg i.p.). The study seems to suggest that (R,S)-3,4-DCPG may possess antipsychotic properties at doses close to those evoking extrapyramidal side-effects which speaks for its rather typical than atypical neuroleptic profile.

Kewords:

(R)-3,4-DCPG,201730-10-1,Neuroscience,GluR, supplier, inhibitor,Antagonist,Blocker,Modulator,Agonist, activators, activates, potent, BioCrick

Online Inquiry

Fill out the information below

* Required Fields

CheckCode: